Search Results - kannan+rangaramanujam

4 Results

Sort By:

Non-surgical treatment for corneal blindness

Value Proposition· Non-surgical, non-invasive treatment for loss of vision caused by corneal damage.· Cost effective to manufacture· Easy application· Regenerates existing cornea structure to restore vision.Unmet NeedThe only curative option for many cases of corneal blindness remains surgical corneal transplantation, a resource‑intensive...

Published: 3/13/2026 | Inventor(s): Kannan Rangaramanujam, Samuel Yiu, Minjie Chen, Siva Pramodh Kambhampati, Hui Lin

Keywords(s):

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Ophthalmology, Clinical and Disease Specializations > Ophthalmology > Corneal Dystrophy, Clinical and Disease Specializations > Ophthalmology > Corneal Neovascularization, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers

Dendrimer-conjugated GCPII Inhibitors to Delay Loss of Muscle Mass and Strength

Value Proposition· GCPII inhibitor has a low IC50 (<5 nM), suggesting greater potency and less systemic toxicity.· Functional improvements after treatment include 95% preservation of muscle mass, 96% preservation of grip strength, 25% greater isometric force.· Decreased decline in neuromuscular transmission compared to control. Technology...

Published: 3/13/2026 | Inventor(s): Barbara Slusher, Yu Su, Kannan Rangaramanujam

Keywords(s):

Category(s): Clinical and Disease Specializations > Musculoskeletal > Muscle Atrophy, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Dendrimer Conjugated Glutamine Antagonists for Targeted Brain and Tumor Delivery

Value Proposition· Deliver glutamine antagonists to the CNS without GI and systemic toxicity assiated with free DON.· High specificity for activated microglia and tumor-associated macrophages, providing therapeutic precision across neuroinflammatory and oncologic indications. · Broad applicability across CNS, cancer, and immune disorders,...

Published: 3/13/2026 | Inventor(s): Barbara Slusher, Rana Rais, Kannan Rangaramanujam, Anjali Sharma, Pavel Majer, Benjamin Bell, Lukas Tenora, Katerina Novotna, Martin Hadzima, Martin Kaiser, Tomas Tichy, Takashi Tsukamoto, Run-Duo Gao, Xiaolei Zhu

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules

Dendrimer-delivered alpha-particle radiotherapy for treatment of glioblastoma and possibly of other cancers in the brain

#C17436Inventor(s): Stavroula Sofou (primary), Kannan Rangaramanujam, Rajiv NairUnmet NeedGlioblastoma accounts for 49.1 percent of all primary malignant brain tumors. Although current standard of care, which includes surgery, followed by radiotherapy, and chemotherapy, may prolong survival, the five-year survival rate for glioblastoma patients is only...

Published: 3/13/2026 | Inventor(s): Stavroula Sofou, Kannan Rangaramanujam, Rajiv Nair

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Glioblastoma, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Immuno-Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms